Kymera Initiates First Patient Dosing in Phase 1b Atopic Dermatitis Trial of KT-621

Kymera Therapeutics, Inc., a biopharmaceutical company based in Watertown, Massachusetts, has made significant progress in its efforts to develop innovative treatments for immunological diseases. The company is pioneering a new class of oral small molecule degrader medicines, which aim to transform the way complex immuno-inflammatory conditions are treated.

Recently, Kymera initiated dosing in its BroADen Phase 1b clinical trial focused on KT-621, a selective and potent oral degrader targeting STAT6. This clinical trial involves patients suffering from moderate to severe atopic dermatitis (AD), a chronic skin condition characterized by inflammation and itchiness. The trial seeks to assess the drug’s safety, tolerability, and pharmacokinetics over a 28-day period, during which approximately 20 adult patients will receive daily doses.

Nello Mainolfi, the company’s founder, president, and CEO, highlighted the importance of KT-621’s advancement in clinical trials. He emphasized the potential of their unique technology to revolutionize treatment options for complex diseases, offering an oral alternative with a profile similar to biologic treatments. Mainolfi is optimistic about KT-621’s ability to alleviate the burden of AD by providing an effective and convenient oral solution.

KT-621 is the first agent in clinical development to target STAT6, a key transcription factor involved in Th2 inflammation, which is central to conditions like AD and asthma. By targeting this pathway, KT-621 has shown promising potential in preclinical studies, demonstrating effects similar to those of dupilumab, a current standard treatment. The goal is to achieve similar efficacy with the convenience of an oral form, potentially expanding treatment access to broader patient populations.

In addition to the Phase 1b trial, Kymera has completed single and multiple ascending dose (SAD/MAD) dosing and follow-up in the KT-621 Phase 1 healthy volunteer trial. Results from this study are expected by June 2025. Furthermore, two parallel Phase 2b trials are planned, focusing on AD and asthma. These trials, set to start in late 2025 and early 2026, aim to accelerate KT-621’s development, paving the way for Phase 3 registration studies targeting various Th2-driven conditions.

KT-621 represents a significant advancement in the treatment of Th2-mediated diseases. It holds promise for transforming therapeutic approaches for more than 130 million patients worldwide suffering from conditions such as AD, asthma, chronic obstructive pulmonary disease (COPD), and other related disorders. By providing a convenient oral medication with biologics-like activity, KT-621 could potentially address the unmet needs in these areas and improve patient outcomes.

Kymera Therapeutics, founded in 2016, has established itself as a leader in the field of targeted protein degradation (TPD). The company’s mission is to develop therapies that address critical health challenges and significantly enhance patients’ lives. By leveraging TPD, Kymera is able to target disease pathways that traditional therapies cannot reach, offering new hope for individuals with complex immunological conditions. As the company continues to advance its clinical pipeline, it remains committed to delivering groundbreaking treatments that can reshape the landscape of immunological disease management.